VRTX

Structural read: VRTX is the cleanest single-asset franchise in large-cap biotech - Trikafta runs at ~$10B annual run-rate with 90%+ CF market share, patents into 2037, and no credible competitor in late-stage trials. The structural question is no longer 'does the cash cow hold' but 'does the post-CF pipeline justify a 30x earnings multiple' as Casgevy ramps slowly ($2M/patient, complex ex-vivo workflow), Journavx launches into a skeptical pain-prescriber base, and inaxaplin/VX-880 sit in mid-stage trials.

Bull case:

- Trikafta franchise is a quasi-utility: ~$10B revenue, 90%+ market share, low-double-digit organic growth from international + young-patient label expansion

- Casgevy is first-mover in CRISPR therapeutics with a ~$30B addressable SCD+beta-thal TAM; CMS Cell & Gene Therapy access model (effective Jan 2025) removes Medicaid reimbursement bottleneck

- Journavx (Nav1.8) is the first new mechanism in acute pain in 20+ years; non-opioid label is a regulatory tailwind as states tighten opioid prescribing

- Net cash position ~$10B funds aggressive BD without dilution; $1B+ R&D spend gives optionality across 4 distinct franchises

Bear case:

- Single-asset concentration risk: ~85% of revenue is one drug (Trikafta) - any safety signal or competitor breakthrough re-rates the whole company

- Casgevy ramp is glacial: ex-vivo CRISPR requires bone marrow conditioning, 1-2 month treatment center stay, only ~50 dosed patients through 2025 vs ~100k US SCD population

- Journavx pricing ($15/pill vs $0.10 generic opioids) requires payer formulary wins that are not guaranteed; commercial launch is the 2026 swing factor

- 30x forward P/E prices in pipeline success - inaxaplin Phase 3 readout (2026) and VX-880 (T1D) are binary; failure compresses multiple to large-pharma comp range (15-18x)